Akero Therapeutics Inc [NASDAQ: AKRO] closed the trading session at $51.71.
The stocks have a year to date performance of 85.87 percent and weekly performance of 105.69 percent. The stock has been moved at 82.59 percent over the last six months. The stock has performed 82.27 percent around the most recent 30 days and changed 80.36 percent over the most recent 3-months.
If compared to the average trading volume of 718.90K shares, AKRO reached to a volume of 15244779 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Akero Therapeutics Inc [AKRO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKRO shares is $57.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKRO stock is a recommendation set at 1.18. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Akero Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on Jan-28-25. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on November 18, 2024, representing the official price target for Akero Therapeutics Inc stock. Previously, the target price had yet another raise to $30, while BofA Securities analysts kept a Neutral rating on AKRO stock.
The Average True Range (ATR) for Akero Therapeutics Inc is set at 3.64 The Price to Book ratio for the last quarter was 4.88, with the Price to Cash per share for the same quarter was set at 10.28.
AKRO stock trade performance evaluation
Akero Therapeutics Inc [AKRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 105.69. With this latest performance, AKRO shares gained by 82.27% in over the last four-week period, additionally plugging by 82.59% over the last 6 months – not to mention a rise of 136.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKRO stock in for the last two-week period is set at 85.30, with the RSI for the last a single of trading hit 90.84, and the three-weeks RSI is set at 80.39 for Akero Therapeutics Inc [AKRO]. The present Moving Average for the last 50 days of trading for this stock 29.13, while it was recorded at 30.93 for the last single week of trading, and 26.11 for the last 200 days.
Akero Therapeutics Inc [AKRO]: An insightful look at the core fundamentals
Akero Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.25 and a Current Ratio set at 17.25.
Earnings per share (EPS) analysis for Akero Therapeutics Inc [AKRO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Akero Therapeutics Inc go to -16.76%.
Akero Therapeutics Inc [AKRO]: Institutional Ownership
There are presently around $106.31%, or 112.59%% of AKRO stock, in the hands of institutional investors. The top three institutional holders of AKRO stocks are: JANUS HENDERSON GROUP PLC with ownership of 6.88 million shares, which is approximately 11.5942%. BLACKROCK INC., holding 5.59 million shares of the stock with an approximate value of $$131.06 million in AKRO stocks shares; and BLACKROCK INC., currently with $$127.43 million in AKRO stock with ownership which is approximately 9.159%.
